Katie Ellias is the Managing Director of the JDRF T1D Fund, a Boston-based venture philanthropy firm launched in 2017. See sector focus and contact routes.
Katie Ellias is the Managing Director of the JDRF T1D Fund, a Boston-based venture philanthropy firm launched in 2017 that accelerates type 1 diabetes (T1D) solutions through equity investments, following over a decade of prior venture capital experience at Endeavour Vision and Sofinnova Partners in medical devices and life sciences. Her investment thesis is exclusively focused on the T1D sector, targeting equity investments in companies developing therapies to cure, prevent, or treat the disease, with a geographic scope centered on the US and Europe where she previously invested. The fund operates as an indication-specific vehicle that creates financial and advisory incentives for biotechs to formalize programs around T1D therapies rather than entertaining diverse pitches like traditional VC firms. Ellias typically serves on the boards of portfolio companies, including current board memberships at DiogenX, Veralox, i2O, Biolinq, Seraxis, Enthera, GentiBio, and Zag Bio, as well as SAB Biotherapeutics where she was appointed in November 2023. Notable portfolio companies include DiogenX, Veralox, and SAB Biotherapeutics, alongside previously sold companies such as P
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Boston.
Investors like Katie Ellias · Full investor directory · Investor access · Company funding database